# A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy

> **NCT02743221** · PHASE2 · COMPLETED · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 154 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Trifluridine/tipiracil + bevacizumab
- **DRUG:** Capecitabine + bevacizumab

## Key facts

- **NCT ID:** NCT02743221
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-29
- **Primary completion:** 2018-01-15
- **Final completion:** 2020-09-01
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2024-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02743221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02743221, "A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02743221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*